BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Graham DY, Hernaez R, Rokkas T. Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut 2022;71:643-50. [PMID: 34750206 DOI: 10.1136/gutjnl-2021-326170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Wang F. Efficacy and safety comparison of Helicobacter pylori eradication between vonoprazan dual therapy versus triple therapy: a systematic review and meta-analysis. Therap Adv Gastroenterol 2022;15:17562848221125308. [PMID: 36268270 DOI: 10.1177/17562848221125308] [Reference Citation Analysis]
2 Zhong Z, Zhan B, Xu B, Gao H. Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization. Helicobacter 2022;:e12916. [PMID: 35939537 DOI: 10.1111/hel.12916] [Reference Citation Analysis]
3 Malfertheiner P, Moss SF, Daniele P, Pelletier C, Jacob R, Tremblay G, Hubscher E, Leifke E, Chey WD. Potassium-Competitive Acid Blocker and Proton Pump Inhibitor–Based Regimens for First-Line Helicobacter pylori Eradication: A Network Meta-Analysis. Gastro Hep Advances 2022;1:824-834. [DOI: 10.1016/j.gastha.2022.06.009] [Reference Citation Analysis]
4 Lai Y, Wei W, Du Y, Gao J, Li Z. Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives. Gut Microbes 2022;14:2120747. [PMID: 36070564 DOI: 10.1080/19490976.2022.2120747] [Reference Citation Analysis]